Below are the 2 most recent journal entries recorded in certes949's InsaneJournal:

Wednesday, December 14th, 2011
12:08 am	Levofloxacin - wikipedia, the free encyclopedia ^ Nelson, JM. ; Chiller, TM. ; Powers, JH. ; Angulo, FJ. (Apr 2007). "Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from utilization in poultry: a public health success story. ". Clin Infect Dis 44 (7): 97780. doi:10. 1086/512369. PMID 17342653. ^ Kawahara, S. (Dec 1998). "[Chemotherapeutic agents under study]". Nippon Rinsho 56 (12): 30969. PMID 9883617. ^ Liu, H. ; Mulholland, SG. (July 2005). "Appropriate antibiotic treating genitourinary infections in hospitalized patients. ". Am J Med 118 Suppl 7A (7): 14S20S. doi:10. 1016/j. amjmed. 2005. 05. 009. PMID 15993673. ^ MacDougall C, Guglielmo BJ, Maselli J, Gonzales R (March 2005). "Antimicrobial drug prescribing for pneumonia in ambulatory care". Emerging Infect. Dis. 11 (3): 3804. PMID 15757551. http://www. cdc. gov/ncidod/EID/vol11no03/04-0819. htm. ^ a b c d e f g h i j Janssen Pharmaceutica (September 2008). "Highlights Of Prescribing Information". U. S. Food and Drug Administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl. pdf. ^ Morrissey, I. ; Hoshino, K. ; Sato, K. ; Yoshida, A. ; Hayakawa, I. ; Bures, MG. ; Shen, LL. (August 1996). "Mechanism of differential activities of ofloxacin enantiomers" (PDF). Antimicrob Agents Chemother 40 (8): 177584. PMC 163416. PMID 8843280. http://aac. asm. org/cgi/reprint/40/8/1775. pdf. ^ a b c d DrugBank (19 February 2009). "Showing drug card for Levofloxacin (DB01137)". Canada. http://www. drugbank. ca/drugs/DB01137. ^ a b - c d Renata Albrecht (19 June 2007). "NDA 20-634/S-045, NDA 20-635/S-048, NDA 21-721/S-013" (PDF). USA: U. S. Food and Drug Administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2007/020634s045,%20020635s048,%20021721s013ltr. pdf. ^ a b - c Renata Albrecht (16 April 2008). "NDA 20-634/S-051, NDA 20-635/S-055, NDA 21-721/S-019". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2008/020634s051,%20020635s055,%20021721s019ltr. pdf. ^ label ^ "Levofloxacin". The American Society of Health-System Pharmacists. http://www. drugs. com/monograph/levofloxacin. html. Retrieved 3 April 2011. ^ Mark J. Goldberger (17 December 1998). "Center for drug evaluation and research". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/nda/98/020634s04_appltr. pdf. ^ a b Mark J. Goldberger. "NDA 20-634/S-008, S-009, NDA 20-635/S-007, S-008". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2000/20635S7,8LTR. PDF. ^ Renata Albrecht,. "NDA 20-634/S-013, NDA 20-635/S-010". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2000/20635S10ltr. pdf. ^ Renata Albrecht. "NDA 20-634/S-025, NDA 20-635/S-022". U. S. Food and Drug Administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2002/20634se1-025,20635se1-022ltr. pdf. ^ Renata Albrecht (23 May 2003). "NDA 20-634/S-027, NDA 20-635/S-026". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2003/20634se1-027,20635se1-026ltr. pdf. ^ Nickel, JC. ; Downey, J. ; Clark, J. ; Casey, RW. ; Pommerville, PJ. ; Barkin, J. ; Steinhoff, G. ; Brock, G. et al. (October 2003). "Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome of males: a randomized placebo-controlled multicenter trial". Urology 62 (4): 6147. doi:10. 1016/S0090-4295(03)00583-1. PMID 14550427. ^ Renata Albrecht (24 November 2004). "NDA 20-634/S-035, NDA 20-635/S-035, NDA 21-721/S-003". U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2004/20634s035,20635s035,21721s003ltr. pdf. ^ Renata Albrecht (8 April 2005). "NDA 20-634/S-037, NDA 20-635/S-038, NDA 21-721/S-002". U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2005/020634s037,020635s038,021721s002ltr. pdf. ^ a b c Renata Albrecht (23 June 2006). "NDA 20-634/S-040, NDA 20-635/S-043, NDA 21-721/S-007". U. S. Federal drug administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2006/020634s040,020635s043,021721s007LTR. pdf. ^ a b - Renata Albrecht (5 May 2008). "NDA 20-634/S-047, NDA 20-635/S-051, NDA 21-721/S-015". U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2008/020634se5-047020635se5-051021721se5-015ltr. pdf. ^ John A. Bosso (1998). "New and Emerging Quinolone Antibiotics". Journal of Infectious Disease Pharmacotherapy 2 (4): 6176. doi:10. 1300/J100v02n04_06. ISSN 1068-7777. http://bubl. ac. uk/archive/journals/jidp/v02n0498. htm#6new. ^ "SYNOPSIS" (PDF). veritasmedicine. com. 6 September 2005. http://download. veritasmedicine. com/PDF/CR002392_CSR. pdf. ^ a b c "ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE 62nd MEETING". U. S. Federal drug administration (FDA). 19 November 1996. http://fqresearch. org/pdf_files/62nd_fda_meeting. pdf. "One interesting case which is not included with this slide for arthralgias would be a 15 yr old boy who received ofloxacin IV on an emergency appendectomy together with not grown a lot more than his 70 inches tall over the last year. The 15th percentile for height for any 15 yr old boy however is 66. 5 inches plus the expected growth rate is around two inches per yearThe third case is articular. This can be a 17-year-old patient who experienced arthropathy as well as the drug hasn't been suspected and also the treatment was continued two following months. It leads to destructive arthropathy of the knees plus the hip and prothesis was performed 36 months later. if an irreversible cartilaginous lesion can take place, it's probable that is going to make trouble down the line and now we can't even anticipate what they are like(sic)" ^ a b Dolui SK, Das M, Hazra A (2007). "Ofloxacin-induced reversible arthropathy inside a child". Journal of Postgraduate Medicine 53 (2): 1445. doi:10. 4103/0022-3859. 32220. PMID 17495385. ^ Division of Special Pathogen and Immunologic Drug Products Summary of Clinical Report on Studies Submitted reacting to a Pediatric Written Request ^ Chalumeau M, Tonnelier S, D'Athis P (June 2003). "Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France". Pediatrics 111 (6 Pt 1): e7149. doi:10. 1542/peds. 111. 6. e714. PMID 12777590. http://pediatrics. aappublications. org/cgi/content/full/111/6/e714. Retrieved 2009-06-29. ^ "SYNOPSIS" (PDF). veritasmedicine. com. http://download. veritasmedicine. com/PDF/CR002392_CSR. pdf. ^ "SYNOPSIS" (PDF). veritasmedicine. com. http://download. veritasmedicine. com/PDF/CR002389_CSR. pdf. ^ "SYNOPSIS" (PDF). USA: veritasmedicine. com. http://download. veritasmedicine. com/PDF/CR002389_CSR. pdf. ^ Shepard CW, Soriano-Gabarro M, Zell ER (October 2002). "Antimicrobial Postexposure Prophylaxis for Anthrax: Adverse Events and Adherence". Emerging Infectious Diseases 8 (10): 112432. PMC 2730317. PMID 12396927. http://www. cdc. gov/ncidod/EID/vol8no10/02-0349. htm. Retrieved 2009-06-30. ^ "DOHMH ALERT #8:Fluoroquinolone-resistant gonorrhea, NYC". NY County Medical Society. 2004-04-30. http://www. nycms. org/article_view. php3view=947&part=1. Retrieved 2009-06-30. ^ Cdc and Prevention (CDC) (October 1995). "Fluoroquinolone resistance in Neisseria gonorrhoeae--Colorado and Washington, 1995". MMWR Morb. Mortal. Wkly. Rep. 44 (41): 7614. PMID 7565558. http://www. cdc. gov/mmwr/preview/mmwrhtml/00039305. htm. ^ Coban S, Ceydilek B, Ekiz F, Erden E, Soykan I (October 2005). "Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection". Ann Pharmacother 39 (10): 173740. doi:10. 1345/aph. 1G111. PMID 16105873. ^ Cahill JB, Bailey EM, Chien S, Johnson GM (January 2005). "Levofloxacin secretion in breast milk: a claim report". Pharmacotherapy 25 (1): 1168. doi:10. 1592/phco. 25. 1. 116. 55616. PMID 15767227. ^ Nardiello S, Pizzella T, Ariviello R (March 2002). "[Risks of antibacterial agents in pregnancy"] (in Italian). Le Infezioni in Medicina 10 (1): 815. PMID 12700435. http://www. infezmed. it/VisualizzaUnArticolo. aspxAnno=2002&numero=1&ArticoloDaVisualizzare=Vol_10_1_2002_1. Retrieved 2009-06-30. ^ Loebstein R, Addis A, Ho E (June 1998). "Pregnancy Outcome Following Gestational Contact with Fluoroquinolones: a Multicenter Prospective Controlled Study". Antimicrobial Agents and Chemotherapy 42 (6): 13369. PMC 105599. PMID 9624471. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=105599. ^ Shin HC, Kim JC, Chung MK (September 2003). "Fetal and maternal tissue distribution on the new fluoroquinolone DW-116 in pregnant rats". Comp. Biochem. Physiol. C Toxicol. Pharmacol. 136 (1): 95102. doi:10. 1016/j. cca. 2003. 08. 004. PMID 14522602. ^ Dan M, Weidekamm E, Sagiv R, Portmann R, Zakut H (February 1993). "Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women". Antimicrob. Agents Chemother. 37 (2): 2936. PMC 187655. PMID 8452360. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=187655. ^ a b Noel GJ, Bradley JS, Kauffman RE (October 2007). "Comparative safety profile of levofloxacin in 2523 children with attention on four specific musculoskeletal disorders". Pediatr. Infect. Dis. J. 26 (10): 87991. doi:10. 1097/INF. 0b013e3180cbd382. PMID 17901792. ^ a b c d e R. W. Johnson (20 December 1996). "Levaquin (Levofloxacin) NDA 20634". USA: U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/nda/96/020634_levaquin_toc. cfm. ^ a b - c "SYNOPSIS". USA. http://download. veritasmedicine. com/PDF/CR002392_CSR. pdf. Retrieved 29 January 2009. ^ "SYNOPSIS". USA. http://download. veritasmedicine. com/PDF/CR002389_CSR. pdf. Retrieved 29 January 2009. ^ Owens Rc, Jr; Ambrose, PG (July 2005). "Antimicrobial safety: consentrate on fluoroquinolones". Clinical Infectious Diseases 41 Suppl 2: S14457. doi:10. 1086/428055. ISSN 1058-4838. PMID 15942881. ^ De Sarro A, De Sarro G (March 2001). "Adverse reactions to fluoroquinolones. an understanding on mechanistic aspects" (PDF). Curr. Med. Chem. 8 (4): 37184. PMID 11172695. http://www. fqresearch. org/pdf_files/cmc. pdf. ^ http://www. fqresearch. org/text_documents/FDA_Medical_Bulletin_1996. doc ^ U S Federal drug administration (8 July 2008). "FDA Requests Boxed Warnings on Fluoroquinolone Antimicrobial Drugs". U. S. Food and Drug Administration (FDA). http://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116919. htm. Retrieved 5 September 2009. ^ US Fda standards (2008). "Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin and generic ofloxacin)"]. USA. http://www. fda. gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084316. htm. Retrieved 5 September 2009. [dead link] ^ a b US Fda. "Drugs at FDA: Approved by the fda Drug Products". USA: U. S. Fda standards (FDA). http://www. accessdata. fda. gov/scripts/cder/drugsatfda/index. cfmfuseaction=Search. Label_ApprovalHistory#apphist. Retrieved 5 September 2009. ^ a b Rosenthal, Norman (November 2008). "Important Difference in the LEVAQUIN (Ievofloxacin) Complete Prescribing Information -Addition of Boxed Warning and Medication Guide Regarding Tendinitis and Tendon Rupture". Ortho-McNeil Janssen Scientific Affairs, LLC. http://www. fqresearch. org/pdf_files/Levaquin_11_2008_ortho_mcneil_dear_dr_letter. pdf. Retrieved 2008-12-27. ^ a b c Renata Albrecht (14 September 2004). "NDA 20-634/S-033, S-034, NDA 20-635/S-033, S-034". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2004/20634s033,034,20635s033,034ltr. pdf. ^ a b Renata Albrecht (14 July 2004). "NDA 19-537/S-053, S-054, NDA 20-780/S-017, S-018". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2004/19537s053,054,20780s017,018ltr. pdf. Retrieved 5 September 2009. ^ a b - Renata Albrecht (18 December 2001). "NDA 20-634/S-015, S-021, S-022, NDA 20-635/S-012, S-019, S-020". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2001/20634s15s21s22ltr. pdf. ^ Renata Albrecht (4 November 2004). "NDA 20-634/S-036, NDA 20-635/S-037". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2004/20635s037,20634s036ltr. pdf. ^ http://www. fqresearch. org/pub_med_levaquin/clostridum_difficicile_pub_med_levaquin. doc ^ a b - Petitjeans, F. ; Nadaud, J. ; Perez, JP. ; Debien, B. ; Olive, F. ; Villevieille, T. ; Pats, B. (December 2003). "A case of rhabdomyolysis with fatal outcome after having a treatment with levofloxacin". Eur J Clin Pharmacol 59 (10): 77980. doi:10. 1007/s00228-003-0688-x. PMID 14576967. ^ a b - Hsiao, SH. ; Chang, CM. ; Tsao, CJ. ; Lee, YY. ; Hsu, MY. ; Wu, TJ. (January 2005). "Acute rhabdomyolysis related to ofloxacin/levofloxacin therapy". Ann Pharmacother 39 (1): 1469. doi:10. 1345/aph. 1E285. PMID 15562138. ^ a b - Korzets, A. ; Gafter, U. ; Dicker, D. ; Herman, M. ; Ori, Y. (November 2006). "Levofloxacin and rhabdomyolysis in a very renal transplant patient". Nephrol Dial Transplant 21 (11): 33045. doi:10. 1093/ndt/gfl396. PMID 16968728. ^ Renata Albrecht (31 May 2007). "NDA 20-634/S-042, NDA 20-635/S-045, NDA 21-721/S-010". U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2007/020634s042,020635s045,021721s010ltr. pdf. ^ Renata Albrecht (19 June 2006). "NDA 19-537/S-062, NDA 20-780/S-023, NDA 19-847/S-037, NDA 19-857/S-042, NDA 21-473/S-016". U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2006/019537s62,020780s23,019847s37,019857s42,021473s16LTR. pdf. Retrieved 5 September 2009. ^ a b Renata Albrecht (5 March 2004). "NDA 20-634/S-029, NDA 20-635/S-029". U. S. Fda (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2004/20634slr029,20635slr029ltr. pdf. ^ Cohen JS (December 2001). "Peripheral Neuropathy Linked to Fluoroquinolones" (PDF). Ann Pharmacother 35 (12): 15407. doi:10. 1345/aph. 1Z429. PMID 11793615. http://fqvictims. org/fqvictims/News/neuropathy/Neuropathy. pdf. ^ Renata Albrecht (15 March 2004). "NDA 19-537/S-048, S-050, S-051 NDA 20-780/S-012, S-014, S-015". U. S. Food and Drug Administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2004/19537slr048,050,051,20780slr012,014,015ltr. pdf. Retrieved September 2009. ^ Renata Albrecht (3 October 2008). "NDA 20-634/S-052, NDA 20-635/S-057, NDA 21-721/S-020". U. S. Food and Drug Administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2008/020634s052,%20020635s057,021721s020ltr%20. pdf. ^ Renata Albrecht (3 October 2008). "NDA 19-537/S-068, NDA 19-847/S-042, NDA 19-857/S-049, NDA 20-780/S-026, NDA 21-473/S-024". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2008/019537s068,019847s042ltr. pdf. Retrieved 5 September 2009. ^ a b - Renata Albrecht (13 December 2007). "NDA 20-634/S-050, NDA 20-635/S-054, NDA 21-721/S-018". U. S. Federal drug administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2007/020634s050,%20020635s054,%20021721s018ltr. pdf. ^ Kushner, JM. ; Peckman, HJ. ; Snyder, CR buy cheap diflucan online. (October 2001). "Seizures regarding fluoroquinolones". Ann Pharmacother 35 (10): 11948. doi:10. 1345/aph. 10359. PMID 11675843. ^ http://www. fqresearch. org/pub_med_levaquin/seizures_pub_med_levaquin. doc ^ Ozawa, TT. ; Valadez, T. (March 2002). "Clostridium difficile infection connected with levofloxacin treatment". Tenn Med 95 (3): 1135. PMID 11898264. ^ Gopal Rao, G. ; Mahankali Rao, CS. ; Starke, I. (March 2003). "Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection receiving care with levofloxacin compared with beta-lactam-based therapy". J Antimicrob Chemother 51 (3): 697701. doi:10. 1093/jac/dkg115. PMID 12615873. ^ Muto CA, Pokrywka M, Shutt K (March 2005). "A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies with a teaching hospital following increased fluoroquinolone use". Infect Control Hosp Epidemiol 26 (3): 27380. doi:10. 1086/502539. PMID 15796280. http://www. journals. uchicago. edu/doi/pdf/10. 1086/502539. ^ Deshpande, A. ; Pant, C. ; Jain, A. ; Fraser, TG. ; Rolston, DD. (February 2008). "Do fluoroquinolones predispose patients to Clostridium difficile associated disease An assessment the evidence". Curr Med Res Opin 24 (2): 32933. doi:10. 1185/030079908X253735. PMID 18067688. ^ Cho, S. ; Breedlove, JJ. ; Gunning, ST. (January 2008). "Radiation recall reaction induced by levofloxacin". J Drugs Dermatol 7 (1): 647. PMID 18246700. ^ http://www. fqresearch. org/pub_med_levaquin/hypoglycemia_pib_med_levaquin. doc ^ http://www. fqresearch. org/pub_med_levaquin/kidney_damage_pub_med_levaquin. doc ^ Smythe, MA. ; Cappelletty, DM. (December 2000). "Anaphylactoid reaction to levofloxacin". Pharmacotherapy 20 (12): 15203. doi:10. 1592/phco. 20. 19. 1520. 34868. PMID 11130225. ^ Takahama, H. ; Tsutsumi, Y. ; Kubota, Y. (September 2005). "Anaphylaxis caused by levofloxacin". Int J Dermatol 44 (9): 78990. doi:10. 1111/j. 1365-4632. 2004. 02325. x. PMID 16135155. ^ Gunduz, A. ; Turedi, S. ; Kalkan, A. ; Nuhoglu, I. (August 2006). "Levofloxacin induced myasthenia crisis". Emerg Med J 23 (8): 662. doi:10. 1136/emj. 2006. 038091. PMC 2564188. PMID 16858118. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=2564188. ^ Mennecier, D. ; Thiolet, C. ; Bredin, C. ; Potier, V. ; Vergeau, B. ; Farret, O. (October 2001). "[Acute pancreatitis after treatment by levofloxacin and methylprednisolone]". Gastroenterol Clin Biol 25 (10): 9212. PMID 11852403. ^ Dominguez Jimenez, JL. ; Bernal Blanco, E. ; Marin Moreno, MA. ; Puente Gutierrez, JJ. (April 2009). "[Acute pancreatitis associated with levofloxacin"] (in Spanish). Gastroenterol Hepatol 32 (4): 3234. doi:10. 1016/j. gastrohep. 2008. 09. 027. PMID 19371975. http://www. elsevier. es/revistas/ctl_servlet_f=7064&ip=94. 7. 35. 23&articuloid=13136637&revistaid=14. ^ a b - Fraunfelder, FW. ; Fraunfelder, FT. (September 2009). "Diplopia and fluoroquinolones". Ophthalmology 116 (9): 18147. doi:10. 1016/j. ophtha. 2009. 06. 027. PMID 19643481. ^ Grepinet, C. ; Guillocheau, E. ; Berteloot, A. ; Vachee, A. ; Herbin, O. ; Gautier, S. ; l'association des centres regionaux de pharmacovigilance (2008). "[Drug-induced fever during treatment with levofloxacin: a case-report]". Therapie 63 (4): 3413. PMID 19043827. ^ Lardizabal, DV. (February 2009). "Intracranial hypertension and levofloxacin: an instance report". Headache 49 (2): 3001. doi:10. 1111/j. 1526-4610. 2008. 01212. x. PMID 18647180. ^ Oh YR, Carr-Lopez SM, Probasco JM, Crawley PG (2003). "Levofloxacin-induced autoimmune hemolytic anemia". Ann Pharmacother 37 (78): 10103. doi:10. 1345/aph. 1C525. PMID 12841809. ^ Iannini, PB. (June 2007). "The safety profile of moxifloxacin along with fluoroquinolones in special patient populations". Curr Med Res Opin 23 (6): 140313. doi:10. 1185/030079907X188099. PMID 17559736. ^ Owens, RC. ; Ambrose, PG. (July 2005). "Antimicrobial safety: consentrate on fluoroquinolones". Clin Infect Dis 41 Suppl 2: S14457. doi:10. 1086/428055. PMID 15942881. ^ Saint, F. ; Gueguen, G. ; Biserte, J. ; Fontaine, C. ; Mazeman, E. (September 2000). "[Rupture of the patellar ligament 4 weeks after treatment with fluoroquinolone]". Rev Chir Orthop Reparatrice Appar Mot 86 (5): 4957. PMID 10970974. ^ Gangopadhyay, N. ; Daniell, M. ; Weih, L. ; Taylor, HR. (April 2000). "Fluoroquinolone and fortified antibiotics for the treatment of bacterial corneal ulcers". Br J Ophthalmol 84 (4): 37884. doi:10. 1136/bjo. 84. 4. 378. PMC 1723447. PMID 10729294. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=1723447. ^ Walter, K. ; Tyler, ME. (August 2006). "Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases". Cornea 25 (7): 8557. doi:10. 1097/01. ico. 0000224642. 43601. 14. PMID 17068466. ^ "Public Citizen Warns of Cipro Dangers". USA: Consumer affairs. 30 August 2006. http://www. consumeraffairs. com/news04/2006/08/pubcit_cipro. html. Retrieved 7 September 2009. ^ "FDA orders 'black box' label on some antibiotics". CNN. 2008-07-08. http://www. cnn. com/2008/HEALTH/07/08/antibiotics. risk/index. html. Retrieved 2008-07-08. ^ Hirano T, Yasuda S, Osaka Y (March 2008). "The inhibitory outcomes of fluoroquinolones on L-carnitine transport in placental cell line BeWo". International Journal of Pharmaceutics 351 (12): 1138. doi:10. 1016/j. ijpharm. 2007. 09. 022. PMID 17977676. ^ Friedrich, LV. ; Dougherty, R. (December 2004). "Fatal hypoglycemia connected with levofloxacin". Pharmacotherapy 24 (12): 180712. doi:10. 1592/phco. 24. 17. 1807. 52348. PMID 15585448. http://www. medscape. com/viewarticle/496197. ^ Melissa Hunt (January 2007). "Levofloxacin: dysglycemia and liver disorders" (PDF). Canadian adverse reaction newsletter (Canada: Health Canada Newsletter) 17 (1). http://www. hc-sc. gc. ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/carn-bcei_v17n1-eng. pdf. [dead link] ^ Levofloxacin can be employed effectively to be a positive control in thorough QT/QTc studies in healthy volunteersTaubel, Jorg; Naseem, A. , Harada, T. , Wang, D. , Arezina, R. , Lorch, U. and Camm, A. J. (2010) (November 2009). "Levofloxacin may be used effectively like a positive control in thorough QT/QTc studies in healthy volunteers". British Journal of Clinical Pharmacology 69 (4): 391400. doi:10. 1111/j. 1365-2125. 2009. 03595. x. PMC 2848412. PMID 20406223. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=2848412. ^ "Showing drug card for Rimantadine (DB00478)". Canada. 23 June 2009. http://www. drugbank. ca/drugs/DB00478. ^ Drlica K, Zhao X (1 September 1997). "DNA gyrase, topoisomerase IV, along with the 4-quinolones". Microbiol Mol Biol Rev. 61 (3): 37792. PMC 232616. PMID 9293187. http://mmbr. asm. org/cgi/pmidlookupview=long&pmid=9293187. ^ Hussy P, Maass G, Tummler B, Grosse F, Schomburg U (June 1986). "Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts". Antimicrob. Agents Chemother. 29 (6): 10738. PMC 180502. PMID 3015015. http://aac. asm. org/cgi/reprint/29/6/1073. pdf. ^ "Mutagenicity of norfloxacin and AM-833 in bacteria and mammalian cells". Rev. Infect. 1 (jstor. org) 10: S148S149. 1988. JSTOR 4454399. ^ Forsgren A, Bredberg A, Pardee AB, Schlossman SF, Tedder TF (May 1987). "Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth". Antimicrobial Agents and Chemotherapy 31 (5): 7749. PMC 174831. PMID 3606077. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=174831. ^ Gootz TD, Barrett JF, Sutcliffe JA (January 1990). "Inhibitory results of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems". Antimicrobial Agents and Chemotherapy 34 (1): 812. PMC 171510. PMID 2158274. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=171510. ^ Lawrence JW, Darkin-Rattray S, Xie F, Neims AH, Rowe TC (February 1993). "4-Quinolones spark a selective loss of mitochondrial DNA from mouse L1210 leukemia cells". Journal of Cellular Biochemistry 51 (2): 16574. doi:10. 1002/jcb. 240510208. PMID 8440750. ^ Elsea SH, Osheroff N, Nitiss JL (5 July 1992). "Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target with the quinolone CP-115,953 in yeast" (PDF). The Journal of Biological Chemistry 267 (19): 131503. PMID 1320012. http://www. jbc. org/cgi/pmidlookupview=long&pmid=1320012. Retrieved 2009-06-03. ^ Suto MJ, Domagala JM, Roland GE, Mailloux GB, Cohen MA (December 1992). "Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity". Journal of Medicinal Chemistry 35 (25): 474550. doi:10. 1021/jm00103a013. PMID 1469702. ^ Enzmann H, Wiemann C, Ahr HJ, Schluter G (April 1999). "Damage to mitochondrial DNA induced from the quinolone Bay y 3118 in embryonic turkey liver". Mutat. Res. 425 (2): 21324. doi:10. 1016/S0027-5107(99)00044-5. PMID 10216214. ^ Kashida Y, Sasaki YF, Ohsawa K (October 2002). "Mechanistic study on flumequine hepatocarcinogenicity working on DNA damage in mice". Toxicological Sciences : the state run Journal with the Society of Toxicology 69 (2): 31721. doi:10. 1093/toxsci/69. 2. 317. PMID 12377980. http://toxsci. oxfordjournals. org/cgi/content/full/69/2/317. Retrieved 2009-06-30. ^ Thomas A, Tocher J, Edwards DI (May 1990). "Electrochemical characteristics of 5 quinolone drugs as well as their affect on DNA damage and repair in Escherichia coli". The Journal of Antimicrobial Chemotherapy 25 (5): 73344. doi:10. 1093/jac/25. 5. 733. PMID 2165050. http://jac. oxfordjournals. org/cgi/pmidlookupview=long&pmid=2165050. Retrieved 2009-06-30. ^ "Fluoroquinolones and Quinolones". The American Academy of Optometry (British Chapter). http://www. academy. org. uk/pharmacy/fluoroq. htm. Retrieved 29 January 2009. ^ Yaseen A. Al-Soud; Najim A. Al-Masoudi (2003). "A new class of dihaloquinolones bearing N'-aldehydoglycosylhydrazides, mercapto-1,2,4-triazole, oxadiazoline and a-amino ester precursors: synthesis and antimicrobial activity". J. Braz. Chem. Soc 14 (5): 790796. doi:10. 1590/S0103-50532003000500014. http://www. scielo. br/scielo. phpscript=sci_arttext&pid=S0103-50532003000500014&lng=es&nrm=iso&tlng=es. "Nevertheless, some quinolones cause damage to the chromosome of eukaryotic cells. 21,22 These findings prompted us to optimize the substituent at C-3, by. . . " ^ Yaseen A. Al-Soud a and Najim A. Al-Masoudi (2003). "A New Class of Dihaloquinolones Bearing N'-Aldehydoglycosylhydrazides, Mercapto-1,2,4-triazole, Oxadiazoline and -Amino Ester Precursors: Synthesis and Antimicrobial Activity". J. Braz. Chem. Soc 14 (5): 790796. doi:10. 1590/S0103-50532003000500014. http://jbcs. sbq. org. br/jbcs/2003/v14_n5/13-048-02. pdf. "Although the present quinolones are certainly not considered to be potent inhibitors of eucaryotic topoisomerases, some effects on these and other enzymes involved with DNA replication have been observed" ^ Sissi C, Palumbo M (November 2003). "The quinolone family: from antibacterial to anticancer agents". Current Medicinal Chemistry 3 (6): 43950. doi:10. 2174/1568011033482279. PMID 14529452. "The present review is targeted on the structural modifications accountable for the transformation of an antibacterial into an anticancer agent. Indeed, a distinctive feature of medicine using the quinolone structure could be the remarkable ability to target different type II topoisomerase enzymes. Particularly, some congeners on this drug family display high activity not merely against bacterial topoisomerases, but in addition against eukaryotic topoisomerases and so are toxic to cultured mammalian cells as well as in vivo tumor models" ^ Brouwers JR (1992). "Drug interactions with quinolone antibacterials". Drug Saf 7 (4): 26881. doi:10. 2165/00002018-199207040-00003. PMID 1524699. ^ Hilliard JJ, Krause HM, Bernstein JI (1995). "A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase". Adv Exp Med Biol. 390: 5969. PMID 8718602. ^ Harder S, Fuhr U, Staib AH, Wolff T (November 1989). "Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations". Am. J. Med. 87 (5A): 89S91S. doi:10. 1016/0002-9343(89)90031-4. PMID 2589393. ^ Cooper JG, Harboe K, Frost SK, Skadberg O (April 2005). "Ciprofloxacin interacts with thyroid replacement therapy". BMJ 330 (7498): 1002. doi:10. 1136/bmj. 330. 7498. 1002. PMC 557149. PMID 15860826. http://www. bmj. com/cgi/content/full/330/7498/1002. ^ Domagala JM (April 1994). "Structure-activity and structure-side-effect relationships with the quinolone antibacterials". J. Antimicrob. Chemother. 33 (4): 685706. doi:10. 1093/jac/33. 4. 685. PMID 8056688. http://jac. oxfordjournals. org/cgi/reprint/33/4/685. ^ Janknegt R (November 1990). "Drug interactions with quinolones". J. Antimicrob. Chemother. 26 Suppl D: 729. PMID 2286594. ^ van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH (2003). "Increased probability of achilles tendon rupture with quinolone antibacterial use, specially in elderly patients taking oral corticosteroids". Arch. Intern. Med. 163 (15): 18017. doi:10. 1001/archinte. 163. 15. 1801. PMID 12912715. http://archinte. ama-assn. org/cgi/content/full/163/15/1801. ^ Zacher, JL; Givone, DM (2004). "False-positive urine opiate screening associated with fluoroquinolone use". Ann Pharmacother (38): 15251528. ^ University of Maryland Hospital. "Levofloxacin". USA: University of Maryland. http://www. umm. edu/altmed/drugs/levofloxacin-075755. htm#U. S. %20Brand%20Names. ^ Takashi Shoda (23 October 2008). "UK Levofloxacin SPC and Underlying Patent Upheld by High Court Patent Court". USA: Daiichi Sankyo, Limited. http://www. daiichisankyo. com/news/yymmdd_nn. htmlb_newsrelease_n1_eng. detail%5Bid%5D=682. 3&b_newsrelease_n1_eng. year_selector%5Bid%5D=682. 3&b_newsrelease_n1_eng. category_selector%5Bid%5D=682. 3. [dead link] ^ Johnson & Johnson (2009). "Analysis of Sales by Business Segments" (PDF). Shareholder. p. 27. http://files. shareholder. com/downloads/JNJ/0x0x171267/057640f8-b2c0-4b0f-9f54-7a24a553c3ce/2007AR. pdf. ^ a b c "LEVAQUIN". USA: drugpatentwatch. com. http://www. drugpatentwatch. com/premium/preview/detail/index. phpsearchtype=alpha&category=Tradename&searchstring=LEVAQUIN. ^ Ed Lamb (1 May 2008). "Top 200 Prescribed drugs of 2007". USA: Pharmacy Times. http://www. pharmacytimes. com/issues/articles/2008-05_003. asp. [dead link] ^ "Levofloxacin". Tuberculosis (Edinb) 88 (2): 11921. March 2008. doi:10. 1016/S1472-9792(08)70013-1. PMID 18486047. ^ North DS, Fish DN, Redington JJ (1998). "Levofloxacin, a second-generation fluoroquinolone". Pharmacotherapy 18 (5): 91535. PMID 9758306. ^ Lemke, Thomas L. ; Williams, David A. (1 October 2007). Foye's Principles of Medicinal Chemistry (6 ed. ). USA: Lippincott Williams & Wilkins. ISBN 978-0781768795. http://books. google. com/id=NHQQBMM-qMEC&pg=PP1. ^ "Levaquin Information". USA: Medications. com. http://www. medications. com/drugs/levaquin. ^ King DE, Malone R, Lilley SH (May 2000). "New classification rrmprove on the quinolone antibiotics". American Family Physician 61 (9): 27418. PMID 10821154. http://www. aafp. org/afp/20000501/2741. html. Retrieved 2009-06-30. ^ Davis R, Bryson HM (April 1994). "Levofloxacin. An assessment of its antibacterial activity, pharmacokinetics and therapeutic efficacy". Drugs 47 (4): 677700. doi:10. 2165/00003495-199447040-00008. PMID 7516863. ^ "STATISTICAL REVIEW AND EVALUATION" (PDF). USA: U. S. Federal drug administration (FDA). 21 November 1996. http://www. accessdata. fda. gov/drugsatfda_docs/nda/96/020634-4. pdf. ^ 2009 shareholders meeting; time stamped at 1 hour 42 minutes ^ [1][dead link] ^ Ed Lamb (1 May 2008). "Top 200 Medications of 2007". Pharmacy Times. http://www. pharmacytimes. com/issues/articles/2008-05_003. asp. Retrieved 21 July 2009. [dead link] ^ Cravit, Cravit Ophthalmic, Elequine, Floxel, Iquix, Leroxacin, Lesacin, Levaquin, Levokacin, Levox, Levoxacin, Mosardal, Nofaxin, Quixin, Reskuin, Tavanic, Volequin http://www. drugbank. ca/drugs/DB01137 ^ Cravox, Floxlevo, Levoxacine, Levoxetina, Nislev, Oftaquix, Prixar, Reskuin, Tavanic source: http://www. umm. edu/altmed/drugs/levofloxacin-075755. htm#International%20Brand%20Names ^ a b - "Novopharm Limited". USA. 3 November 2009. http://investing. businessweek. com/research/stocks/private/snapshot. aspprivcapId=4240255. ^ JOHNSON & JOHNSON (28 March 2004). "UNITED STATES SECURITIES AND EXCHANGE COMMISSION". USA: shareholder. com. pp. 2829. http://apps. shareholder. com/sec/viewerContent. aspxcompanyid=JNJ&docid=2940855. ^ "NDA 20-634/S-054, NDA 20-635/S-059, NDA 21-721/S-022". U. S. Fda standards (FDA). 12 March 2009. http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2009/020634s054,020635s059,021721s022ltr. pdf. ^ Ozlem Belen (27 March 2009). "NDA 20-634/S-053, NDA 20-635/S-058, NDA 21-721/S-021". U. S. Food (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2009/020634s053,020635s058,021721s021lt. pdf. ^ Ortho-McNeil-Janssen Pharmaceuticals, Inc. (October 2008). "FDA-Approved Medication Guide". U. S. Fda standards (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/label/2009/020634s053,020635s058,%20021721s021lbl. pdf. ^ Levaquin (Levofloxacin) ^ Renata Albrecht (3 October 2008). "NDA 19-735/S-059". U. S. Federal drug administration (FDA). http://www. accessdata. fda. gov/drugsatfda_docs/appletter/2008/019735s059ltr. pdf. ^ Bailey RR, Natale R, Linton AL (October 1972). "Nalidixic acid arthralgia". Can Med Assoc J 107 (7): 604 passim. PMC 1940945. PMID 4541768. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=1940945. ^ Bailey RR, Kirk JA, Peddie BA (July 1983). "Norfloxacin-induced rheumatic disease". N Z Med J 96 (736): 590. PMID 6223241 purchase avelox online. ^ Szarfman A, Chen M, Blum MD (January 1995). "More on fluoroquinolone antibiotics and tendon rupture" (letter). N Engl J Med 332 (3): 193. doi:10. 1056/NEJM199501193320319. PMID 7800023. ^ a b - "Petition to want a reminder on All Fluoroquinolone Antibiotics (HRG Publication #1399)". Public Citizen. August 1, 1996. http://www. citizen. org/publications/release. cfmID=6595. Retrieved on December 27, 2008. ^ "Reports of adverse events with fluoroquinolones". FDA Medical Bulletin 26 (3). October 1996. http://www. fda. gov/medbull/oct96/adverse. html. [dead link] Retrieved on December 27, 2008. alternate link: http://www. fqresearch. org/text_documents/FDA_Medical_Bulletin_1996. doc ^ a b "Madigan, Public Citizen, petition FDA for "black box" warning regarding potential negative effects of certain popular antibiotics" (Blog post). Office in the Illinois Attorney General. August 29, 2006. http://www. illinoisattorneygeneral. gov/pressroom/2006_08/20060829. html. Retrieved 2008-12-27. Full text of the 2005 petition and FDA response which is available from the Fluoroquinolone Toxicity Research Foundation, a U. S. consumer advocacy group. ^ a b "Public Citizen Petitions the FDA to feature a Black Box Warning on Fluoroquinolone Antibiotics (HRG Publication #1781)". Public Citizen. August 29, 2006. http://www. citizen. org/publications/release. cfmID=7453. Retrieved 2008-12-27. ^ "Public Citizen v. Food and Drug Administration (FDA) (Fluoroquinolone)". Public Citizen. January 3, 2008. http://www. citizen. org/litigation/forms/cases/CaseDetails. cfmcID=444. Retrieved 2008-12-27. ^ Ravn, Karen (August 18, 2008). "Behind the FDA's 'black box' warnings". La Times. http://articles. latimes. com/2008/aug/18/health/he-closer18. Retrieved 2008-12-27. ^ "FDA Requests Boxed Warnings on Fluoroquinolone Antimicrobial Drugs" (Press release). U. S. Fda. 2008-07-08. http://www. fda. gov/bbs/topics/NEWS/2008/NEW01858. html. Retrieved 2008-10-11. ^ FDA Requests Boxed Warnings on Fluoroquinolone Antimicrobial Drugs ^ MacCarthy, Paul (October 22, 2008). "Important Alternation in the Avelox (moxifloxacin hydrochloride) and Cipro (ciprofloxacin) Complete Prescribing Information Addition of Boxed Warning and Medication Guide Regarding Tendinitis and Tendon Rupture". Bayer HealthCare Pharmaceuticals. http://www. cipro. com/html/pdf/dhpl. pdf. Retrieved 2008-12-27. ^ M Jacobs, Worldwide Breakdown of Antimicrobial Resistance. International Symposium on Antimicrobial Agents and Resistance 2005. ^ Robicsek A, Jacoby GA, Hooper DC (October 2006). "The worldwide emergence of plasmid-mediated quinolone resistance". The Lancet Infectious Diseases 6 (10): 62940. doi:10. 1016/S1473-3099(06)70599-0. PMID 17008172. ^ Jim Hoover, for Bayer Corporation, Alaska Pharmacy and Therapeutics Committee March 19, 2004 ^ Froom J, Culpepper L, Jacobs M (July 1997). "Antimicrobials for acute otitis media An evaluation from the International Primary Care Network". BMJ (Clinical Research Ed. ) 315 (7100): 98102. PMC 2127061. PMID 9240050. http://www. pubmedcentral. nih. gov/articlerender. fcgitool=pmcentrez&artid=2127061. ^ Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS (March 2005). "Fluoroquinolone prescribing in the United States: 1995 to 2002". The American Journal of drugs 118 (3): 25968. doi:10. 1016/j. amjmed. 2004. 09. 015. PMID 15745724. ^ K08 HS14563 and HS11313 ^ Public Citizen; Michael T. Kickpatrick (3 January 2008). "In North america District Court For your District Of Columbia" (PDF). USA: Carey & Danis, LLC. Archived from the original on 2008. http://www. fqresearch. org/fda_suit. htm. ^ Lisa Madigan (18 May 2005). "Office Of The Attorney General State Of Illinois, CITIZEN PETITION". U. S. Food (FDA). Archived on the original on 2005. http://www. fqresearch. org/pdf_files/fda_response. pdf. ^ Jane A. Axelrad (16 November 2005). "Re: Docket No. 2005P-0205". U. S. Food (FDA). http://www. fqresearch. org/pdf_files/illinois. pdf. ^ Michael A. Friedman, M. D. (9 June 1998). "Petition to your Food to instantly stop the distribution of dangerous, misleading prescription drug information to your public. (HRG Publication #1442)". USA: Public Citizen. Archived from your original on 2007. http://fqresearch. org/HRG_Publication_1442. htm. ^ Public Citizen. "Patently Offensive: Congress Set to increase Monopoly Patents for Cipro along with other Drugs". USA: Citizen. org. http://www. citizen. org/print_article. cfmID=6435. [dead link] ^ "SYNOPSIS" (PDF). USA: Veritas Medicine. 30 June 2004. http://download. veritasmedicine. com/PDF/CR002389_CSR. pdf. Retrieved 13 August 2009. ^ Susan Todd (January 15, 2010). "Johnson&Johnson charged with paying kickbacks to pharmacy chain Omnicare". The Star-Ledger. http://www. nj. com/business/index. ssf/2010/01/johnsonjohnson_accused_of_payi. html. ^ Natasha Singer (January 15, 2010). "Johnson & Johnson Charged with Drug Kickbacks". The brand new York Times. http://www. nytimes. com/2010/01/16/business/16drug. html. ^ [2][dead link] ^ "Levaquin MDL 08-MD-1943". USA: US District Court District of Minnesota. http://www. mnd. uscourts. gov/MDL-Levaquin/index. shtml. Retrieved 7 September 2009. ^ Charles Toutant (6 July 2009). "Litigation Over Johnson & Johnson Antibiotic Levaquin Designated N. J. Mass Tort". New Jersey Law Journal. http://www. law. com/jsp/article. jspid=1202431984309. ^ Reed Abelson; Natasha Singer (October 14, 2011). "Johnson & Johnson Wins Suit Over Antibiotic's Side Effects". The brand new York Times. http://www. nytimes. com/2011/10/15/business/johnson-johnson-wins-suit-over-levaquins-side-effects. html. ^ Carey and Danis LLC (3 September 2009). "Carey and Danis LLC Announces Four Lawsuits up against the Makers of Levaquin". Reuters. http://www. reuters. com/article/pressRelease/idUS199242+03-Sep-2009+BW20090903. ^ The Southeast Texas Record. Apr. 17, 2010 S. E. Texas' Legal Journal Class action lawsuit alleges antibiotic causes tendon damage 4/15/2010 8:21 AM By Michelle Massey, East Texas Bureau http://www. setexasrecord. com/news/226050-class-action-alleges-antibiotic-causes-tendon-damage ^ The United States District Court District Of Minnesota (12 May 2009). "DEFENDANT JOHNSON & JOHNSON'S Respond to PLAINTIFF'S COMPLAINT" (PDF). USA. http://www. fqresearch. org/pdf_files/232-1. pdf. [dead link] ^ $1,800,000. 00 Verdict Obtained for Man Injured because of the Drug Levaquin. Source: http://www. seedol. com/20116773-mikal-watts-obtains-first-levaquin-verdict-in-the-nation. html ^ "Anthrax Scare Leaves Trail of Cipro Victims - Class Actions filed into two States". USA: Sheller Ludwig & Sheller. 17 October 2003. http://www. sheller. com/NewsDetails. aspNewsID=72. Retrieved 9 September 2009. [dead link] ^ "LEGAL BRIEF of Postal Employees Cases (EEOC, MSPB, District Courts)". USA: Postal Reporter. http://www. lunewsviews. com/legal_briefs_archives. htm#cipro. Retrieved 9 September 2009. ^ Charles P. Goodell, Jr. "Profile". USA: Goodell, DeVries, Leech & Dann, LLP. http://www. gdldlaw. com/content/bio_goodell. htm. Retrieved 9 September 2009. . Current Mood: ecstatic (Comment on this)
Tuesday, December 13th, 2011
10:29 pm	Clonidine to deal with migraine : review drug. Brand names Catapres, Catapres Periongets, Dixarit Used inside following combined preparations None GENERAL INFORMATION Clonidine has central and peripheral actions within your body. The drug decreases impulses from the brain that keep high blood pressure up, and increases activity in nerve pathways which help lower blood pressure level. Clonidine has additionally been given for other difficulties including migraine, menopausal hot flushes, and withdrawal symptoms during drug detoxification. Its main drawback is the fact, when used in the doses instructed to control blood pressure, there might be a serious rise in blood pressure level if doses are missed or if the drug is stopped suddenly. Its use to treat hypertension has largely been superseded by other drugs. INFORMATION FOR USERS Your drug prescription is tailored for you. Will not alter dosage without checking along with your doctor. How taken Tablets, SR-capsules, injection. Frequency and timing of doses 1-3 x daily. Adult dosage range High blood pressure 0. 15mg -1,2mg daily. Doses of up to 2. 4mg daily have been utilized in some resistant cases. Migraine 100-150mcg daily. Onset of effect 2-5 hours (by mouth); 10 mins (injection). Duration of action 6-20 hours buy cheap modalert online. Diet advice None. Storage Keep inside a closed container in a very cool, dry place out from the reach of children. Missed dose Take as early as you remember. In case your next dose is due within 2 hours, take a single dose now and skip the subsequent. Stopping the drug Do not quit taking the drug without conferring with your physician, which will supervise a gradual cut in dosage. Abrupt withdrawal might result in a hazardous rise in blood pressure levels. Exceeding the dose An occasional unintentional extra dose is unlikely to cause problems. You may experience vomiting or drowsiness. Notify your physician. POSSIBLE ADVERSE EFFECTS Clonidine may cause drowsiness, dry mouth, and constipation. These effects usually decrease after long-term therapy. An adjustment in dosage might help. QUICK REFERENCE Drug group Antihypertensive drug and drug for migraine Overdose danger rating Medium Dependence rating Low Prescription needed Yes Available as generic No SPECIAL PRECAUTIONS Be guaranteed to tell your doctor if: You have experienced depression. You have poor circulation. You might have heart disease. You consider other medications. Pregnancy No proof of risk, but other drugs is much more suitable. Request information from your doctor. Breast-feeding The drug passes into your breast milk and could customize the baby. Talk to your doctor. Infants and children Not recommended. Over 60 No special problems. Driving and hazardous work Avoid such activities til you have learned how clonidine affects you because the drug might cause drowsiness. Alcohol Avoid. Alcohol could raise the sedative link between this drug. INTERACTIONS Tricyclic antidepressant drugs may slow up the effect of clonidine. Sedatives The sedating outcomes of clonidine could be enhanced if other drugs with a sedative effect are taken. Beta blockers It comes with an increased chance a critical surge in blood pressure level if clonidine is stopped. PROLONGED USE The more prevalent adverse reactions, including drowsiness, constipation, and xerostomia, may decrease with long- term use. . Current Mood: cranky (Comment on this)